PTO Finds Stem Cell Patent Anticipated, Obvious in Light of 'Significant Guideposts'
By Tony Dutra and Joyce Cutler,
The Bureau of National Affairs
| 05. 12. 2010
[Quotes CGS's Jesse Reynolds]
The Board of Patent Appeals and Interferences at the Patent and Trademark Office found April 28 that a patent on human embryonic stem cells was invalid as anticipated by an earlier patent and obvious in light of the "significant guideposts" in the literature for deriving the cells at the time of invention (
Foundation for Taxpayer and Consumer Rights v. Wisconsin Alumni Research Foundation, B.P.A.I., No. 2010-001854, 4/28/10).
The patent is one of three on stem cell derivation assigned to Wisconsin Alumni Research Foundation and licensed to Geron Corp. It was challenged by consumer advocacy groups in a PTO inter partes reexamination proceeding.
One of the challengers was also successful recently in the Myriad case challenging gene patenting on Section 101 grounds. A stakeholder in the biotechnology industry suggested that both cases represent a "pushback" against the "land rush" for intellectual property in the field.
Challenge by PUBPAT and Consumer Watchdog.
A patent (7,029,913) was issued April 18, 2006, to James A. Thomson titled "Primate embyronic stem cells," with claims drawn to pluripotent human embryonic stem, or ES, cells derived...
Related Articles
By Megan Mineiro and Caroline Kitchener, The New York Times | 10.05.2025
Kathleen Whipple and her husband had dreamed of a big family, but struggled to conceive.
Upon his return from an overseas deployment with the Navy, the couple learned from a fertility doctor that her husband’s sperm count was half of...
By Alondra Nelson, Science | 09.11.2025
In the United States, the summer of 2025 will be remembered as artificial intelligence’s (AI’s) cruel summer—a season when the unheeded risks and dangers of AI became undeniably clear. Recent months have made visible the stakes of the unchecked use...
By Emma McDonald Kennedy
| 09.25.2025
In the leadup to the 2024 election, Donald Trump repeatedly promised to make IVF more accessible. He made the commitment central to his campaign, even referring to himself as the “father of IVF.” In his first month in office, Trump issued an executive order promising to expand IVF access. The order set a 90-day deadline for policy recommendations for “lowering costs and reducing barriers to IVF,” although it didn’t make any substantive reproductive healthcare policy changes.
The response to the...
By Johana Bhuiyan, The Guardian | 09.23.2025
In March 2021, a 25-year-old US citizen was traveling through Chicago’s Midway airport when they were stopped by US border patrol agents. Though charged with no crime, the 25-year-old was subjected to a cheek swab to collect their DNA, which...